Literature DB >> 23316089

Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.

Katherine A Maclean1, Jeannie-Marie S Leoutsakos, Matthew W Johnson, Roland R Griffiths.   

Abstract

A large body of historical evidence describes the use of hallucinogenic compounds, such as psilocybin mushrooms, for religious purposes. But few scientific studies have attempted to measure or characterize hallucinogen-occasioned spiritual experiences. The present study examined the factor structure of the Mystical Experience Questionnaire (MEQ), a self-report measure that has been used to assess the effects of hallucinogens in laboratory studies. Participants (N=1602) completed the 43-item MEQ in reference to a mystical or profound experience they had had after ingesting psilocybin. Exploratory factor analysis of the MEQ retained 30 items and revealed a 4-factor structure covering the dimensions of classic mystical experience: unity, noetic quality, sacredness (F1); positive mood (F2); transcendence of time/space (F3); and ineffability (F4). MEQ factor scores showed good internal reliability and correlated with the Hood Mysticism Scale, indicating convergent validity. Participants who endorsed having had a mystical experience on psilocybin, compared to those who did not, had significantly higher factor scores, indicating construct validity. The 4-factor structure was confirmed in a second sample (N=440) and demonstrated superior fit compared to alternative models. The results provide initial evidence of the validity, reliability, and factor structure of a 30-item scale for measuring single, hallucinogen-occasioned mystical experiences, which may be a useful tool in the scientific study of mysticism.

Entities:  

Year:  2012        PMID: 23316089      PMCID: PMC3539773          DOI: 10.1111/j.1468-5906.2012.01685.x

Source DB:  PubMed          Journal:  J Sci Study Relig        ISSN: 0021-8294


  16 in total

1.  The phenomenon of quantum change.

Authors:  William R Miller
Journal:  J Clin Psychol       Date:  2004-05

2.  Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire.

Authors:  M J Baggott; J R Coyle; E Erowid; F Erowid; L C Robertson
Journal:  Drug Alcohol Depend       Date:  2010-10-28       Impact factor: 4.492

3.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

4.  Brain activity in near-death experiencers during a meditative state.

Authors:  Mario Beauregard; Jérôme Courtemanche; Vincent Paquette
Journal:  Resuscitation       Date:  2009-07-01       Impact factor: 5.262

5.  Use patterns and self-reported effects of Salvia divinorum: an internet-based survey.

Authors:  Matthew J Baggott; Earth Erowid; Fire Erowid; Gantt P Galloway; John Mendelson
Journal:  Drug Alcohol Depend       Date:  2010-10-01       Impact factor: 4.492

Review 6.  Psychedelic drugs and mystical experience.

Authors:  W N Pahnke
Journal:  Int Psychiatry Clin       Date:  1969

7.  Can feelings be enumerated?

Authors:  K W Back; L B Bourque
Journal:  Behav Sci       Date:  1970-11

8.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Authors:  R R Griffiths; W A Richards; U McCann; R Jesse
Journal:  Psychopharmacology (Berl)       Date:  2006-07-07       Impact factor: 4.530

9.  Standards for Internet-based experimenting.

Authors:  Ulf-Dietrich Reips
Journal:  Exp Psychol       Date:  2002

10.  Psychometric evaluation of the altered states of consciousness rating scale (OAV).

Authors:  Erich Studerus; Alex Gamma; Franz X Vollenweider
Journal:  PLoS One       Date:  2010-08-31       Impact factor: 3.240

View more
  69 in total

1.  Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-10-06       Impact factor: 4.153

Review 2.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

3.  The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Authors:  Alan K Davis; Joseph P Barsuglia; Rafael Lancelotta; Robert M Grant; Elise Renn
Journal:  J Psychopharmacol       Date:  2018-04-30       Impact factor: 4.153

4.  A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

Authors:  E Dakwar; E V Nunes; C L Hart; M C Hu; R W Foltin; F R Levin
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

5.  Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.

Authors:  Alexander V Lebedev; Martin Lövdén; Gidon Rosenthal; Amanda Feilding; David J Nutt; Robin L Carhart-Harris
Journal:  Hum Brain Mapp       Date:  2015-05-22       Impact factor: 5.038

6.  High dose psilocybin is associated with positive subjective effects in healthy volunteers.

Authors:  Christopher R Nicholas; Kelsey M Henriquez; Michele C Gassman; Karen M Cooper; Daniel Muller; Scott Hetzel; Randall T Brown; Nicholas V Cozzi; Chantelle Thomas; Paul R Hutson
Journal:  J Psychopharmacol       Date:  2018-06-27       Impact factor: 4.153

Review 7.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

8.  Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.

Authors:  Alan K Davis; Frederick S Barrett; Roland R Griffiths
Journal:  J Contextual Behav Sci       Date:  2019-11-16

9.  Long-term follow-up of psilocybin-facilitated smoking cessation.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Roland R Griffiths
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-21       Impact factor: 3.829

10.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Authors:  Theresa M Carbonaro; Matthew W Johnson; Ethan Hurwitz; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2017-11-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.